Replies to post #393860 on Amarin Corp Plc (AMRN)

[ralphey]

Combo pill vastor would make it clear RX is for REDUCE IT indications . However insurers would then split Rx into generic epa and statin and we are back to who actually is doing the infringing - but that is a much clearer case than just a single rx for Vascepa where one could argue its for hypertriglyceridemia

[ziploc_1]

If there is any chance of Amarin issuing a FDC drug (with statin plus MND-2119), we need to hear details about it NOW...before Amarin stock price drops still further!...The patented gelatin capsule will apparently not be coming to the rescue of Vascepa ...Something more is needed...and the good news is that it is available from this combo drug.

This new patented drug is Amarin's main opportunity to take itself out of the doldrums and redeem itself, recapturing the AMERICAN market with a superior and less expensive formulation of EPA.

Its a pity that Amarin management did not embark upon a pursuit of this new drug long ago when Craig Granowitz was chief of R and D.